Evidence map›Paper›PMID 35367903›Full record

ArticleThe International journal on drug policy2022

Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges.

Brendan P Jacka, Laurie B Bazerman, Collin Dickerson, Marc Moody, Johanna Martin, Emily Patry, Treniece Cady, Hacheming Compere, Matthew Boudreau, Curt G Beckwith

Open access · hybridAbstract read
In one paragraph

Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Brendan P JackaDepartment of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
Laurie B BazermanDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Collin DickersonThe Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Marc MoodyRhode Island Department of Corrections, Pawtucket, Rhode Island, USA.
Johanna MartinDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Emily PatryDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Treniece CadyDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Hacheming CompereDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Matthew BoudreauDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
Curt G BeckwithDivision of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA; The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. Electronic address: cbeckwith@lifespan.org.
Miriam Hospital · USBrown University · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI Ju Nyeong Park · 2018 to 2026
$23.4M
NIAID NIH HHS P30 AI042853NIGMS NIH HHS P20 GM125507
6 · The paper itself

Abstract

backgroundPersons involved with the justice system have an elevated risk of hepatitis C virus (HCV) yet remain marginalized from treatment. Efforts to eliminate HCV will require targeted interventions within the justice system effective at providing diagnosis and treatment.

methodsWe implemented a novel HCV screening and treatment intervention for persons under community supervision in Rhode Island, USA during April 2018--March 2020. Participants received rapid point-of-care HCV antibody testing onsite and referral to community laboratory and treatment services as indicated. We assessed the HCV care cascade to identify areas for improvement.

resultsOverall, 483 individuals were screened for HCV antibody; 85 (18%) were positive. A minority of participants with positive HCV antibody tests (n=25/85, 29%) presented to community laboratories for confirmatory testing. Among participants that received HCV viral load results and linked to a treatment provider (n=12), four initiated treatment, three had record of completing treatment, and two were confirmed to have achieved cure.

conclusionLinkage to HCV viral load testing and treatment was challenging in this community supervision population, with substantial loss to follow-up at each step of the HCV cascade. Community supervision remains an important venue for case identification but substantial barriers to accessing HCV treatment exist. Innovative HCV diagnosis and treatment strategies are needed for community supervision populations.

Indexed as

HepacivirusHepatitis CFeasibility StudiesHepatitis C AntibodiesHumansMass ScreeningHepatitis C AntibodiesCare cascadeHCV eliminationhealthcare access

Identifiers

PMID35367903
PMCPMC9070602
OpenAlexW4220947119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.